Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03463057 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL(HO151DLBCL) | active not recruiting | Phase 2 | 109 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Sep 23, 2026 | clinicaltrials |
| NCT04662255 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)(BRUIN-MCL-321) | active not recruiting | Phase 3 | 500 | Loxo Oncology, Inc.INDUSTRY |
| 24 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT04732845 | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | active not recruiting | Phase 1 | 18 | Benjamin TomlinsonOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00039676 | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | active not recruiting | — | 1,836 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00352924 | Agriculture Health Study | active not recruiting | — | 89,655 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05231629 | Sequential Therapy in Multiple Myeloma Guided by MRD Assessments(MASTER-2) | active not recruiting | Phase 2 | 300 | University of Alabama at BirminghamOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05471843 | Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 125 | BeOne MedicinesINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT01829958 | Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | active not recruiting | N/A | 201 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT04096066 | A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant(KRdvsRd) | active not recruiting | Phase 3 | 84 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04920084 | A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | active not recruiting | N/A | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04439253 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | active not recruiting | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04933539 | Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05013190 | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | active not recruiting | — | 72 | TakedaINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05025800 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07809594 | CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma(GZLTCST0001) | active not recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03672318 | Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04071457 | S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration(DRAMMATIC) | active not recruiting | Phase 3 | 1,100 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 17, 2026 | clinicaltrials |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,230 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT02446236 | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 | 27 | Hackensack Meridian HealthOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04462328 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | active not recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04635189 | Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | active not recruiting | Phase 2 | 28 | University of RochesterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04883242 | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04938232 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | active not recruiting | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05944562 | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05949944 | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01841723 | Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03004287 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | active not recruiting | Phase 2 | 50 | University of ArkansasOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | active not recruiting | Phase 2 | 83 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | active not recruiting | Phase 2 | 340 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 15, 2026 | clinicaltrials |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | active not recruiting | Phase 2 | 69 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04497961 | A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide | active not recruiting | Phase 2 | 95 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04756401 | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 8 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06002828 | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | active not recruiting | — | 2,000 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06049134 | Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy | active not recruiting | Phase 4 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06215118 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | active not recruiting | Phase 1 | 100 | PfizerINDUSTRY | 3 | Sep 15, 2026 | clinicaltrials |
| NCT06303167 | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06308822 | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06647732 | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | active not recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 107 | Acerta Pharma BVINDUSTRY | 7 | Sep 14, 2026 | clinicaltrials |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | active not recruiting | Phase 3 | 689 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04246086 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 237 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04270266 | Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma | active not recruiting | N/A | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06242834 | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 11 | Northwestern UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials